Q-omics provides the consensus-scored KRR1P1 profile across patient tissues and cancer cell-line models. KRR1P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, KRR1P1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, KRR1P1 RNA expression shows 19,604 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, and THYM as cancer lineages where KRR1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRR1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRR1P1 survival associations across molecular data types. KRR1P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRR1P1 RNA expression–survival associations across cancer types. High KRR1P1 expression shows unfavorable associations in COAD, MESO, KIRC and ACC, but favorable associations in READ and LAML. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for KRR1P1 RNA expression.
This table summarizes KRR1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRR1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRR1P1 shows lower tumor expression in KICH and BRCA and higher tumor expression in COAD, KIRP, PRAD and LIHC. The COAD box plot shows higher KRR1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.261, t-test p = .001).
This table shows molecular features associated with KRR1P1 in patient tissues and cancer cell lines. In patient samples, KRR1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
